Ogilvy lands Endo pain, men's health work

Share this article:
Ogilvy lands Endo pain, men's health work
Ogilvy lands Endo pain, men's health work

Endo Health Solutions has named Ogilvy Public Relations (Ogilvy PR) as agency partner for its pharmaceutical business. Oglivy PR will offer communications support to the company's men's health and pain-management businesses.

PRWeek reported that the selection process took place over a few weeks and that it is an annual deal.

“Ogilvy's healthcare expertise combined with its global network and resource make this the right partnership as Endo broadens its reach in branded pharmaceuticals,” stated Blaine Davis, Endo SVP, corporate affairs, in a press release.

Endo Pharmaceuticals owns two testosterone injections, Delatestyrl and Fortesta, in addition to a number of pain management products, including Opana ER as well as Percocet, Percodan, Voltaren and Zydone.

Other brands include Fortesta Gel for Low-T, Supprelin LA for central precocious puberty, and bladder cancer treatment Valstar.

The FDA decided last spring to allow generic competition for Opana ER. Endo's 2013 third-quarter earnings presentation notes that commercial support for the brand is continuing, with a focus on driving organic growth through specialty promotion. Endo Health bought Canadian drugmaker Paladin Labs last November, netting the firm pain drug Zohydro, a non-combination hydrocodone product.

FDA approved Zohydro in late October, only one day after federal regulators announced that it would aim to tighten the control of hydrocodone products, like Vicodin, in an effort to reduce misuse and abuse of these products, by moving them from Schedule III to Schedule II.

Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...